The best GLP-1 drug for weight loss as of 2025 is tirzepatide, marketed as Zepbound (for weight loss) and Mounjaro (for diabetes). Tirzepatide has been shown in clinical trials to produce the most substantial weight loss among GLP-1 medications, with average losses of up to 22.5% of body weight. Semaglutide (Wegovy and Ozempic) is another highly effective option, delivering about 15–16% weight loss on average. Both drugs work by regulating appetite, slowing digestion, and improving insulin function. Among FDA- approved GLP-1 drugs specifically for weight management are Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide). Tirzepatide tends to show the greatest mean weight loss and is also approved for conditions like obstructive sleep apnea. Semaglutide is favored for patients with cardiovascular or kidney conditions due to broader FDA approvals. Saxenda offers effective weight loss but is less potent than Wegovy and requires daily injections. There are also oral GLP-1 drugs (like Rybelsus) that are generally less effective but might suit those who prefer not to use injections. In summary:
Drug| Average Weight Loss (%)| Administration| FDA Approval for Weight Loss|
Special Notes
---|---|---|---|---
Tirzepatide (Zepbound)| Up to 22.5%| Weekly injection| Yes| Most effective,
also for sleep apnea
Semaglutide (Wegovy)| ~15–16%| Weekly injection| Yes| Preferred for
cardiovascular/kidney
Liraglutide (Saxenda)| ~8%| Daily injection| Yes| Requires more frequent
dosing
Oral GLP-1 (Rybelsus)| Lower effectiveness| Oral daily| No| Suitable for
injection-averse patients
Tirzepatide currently is the best GLP-1 medication for weight loss based on effectiveness, with semaglutide close behind as the second most effective option. Choice of drug may depend on individual health conditions and preferences.
